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Objec t ives :  To  de termine the
therapeutically equivalent doses of
inhaled versus oral steroids in the
treatment of adults with chronic
asthma.
Search strategy: The Cochrane
Col labora t ion  A i rways  Group
conducted  a  search  in
M E D L T N E (  r 9 6 6 -  r 9 9 9 ) ,  E M B A S E
(1980-1999)  and CINAHL {1982 '
1 9 9 9 ) ,  T h e  s e a r c h  i n c l u d e d
CENTRAL a database containing
potential Randomised Controlled
Trials (RCT) obtained by hand
searching of journals within the
Cochrane Collaboration.
Selection criteria: Randomised
controlled trials of at least 4 weeks
duration were selected and included
persons over the age of | 5 years with
chron ic  as thma.  Tr ia ls  wh ich
compared inhaled steroids and oral
prednisolone or prednisone were
considered;the maximum daily dose
for inhaled steroids was 2000 mcg
and for oral steroids was 60 mg.
Data collection & analysis:Two
independent reviewers screened
| 285 titles and abstracts from the
electronic search. From the results
of the screened electronic search,
bibliography searches and other
contacts,  the reviewers
independently selected l5 trials of
which l0 met previously defined
inclusion criteria.The two reviewers
independently abstracted study
charac ter is t i cs .  and ou tcome
measures.
Main results:All trials were small
and no data could be pooled. Data
from six trials produced the same
pattern, in which prednisolone 7.5-
12 mglday appeared to be as
effective as inhaled steroid 300-2000
mcg/day. Intwo trials, inhaled steroid
300-400 mcg/day was more effective
than prednisolone 5 mg/day. Al l
doses of inhaled steroid appeared to
be more effective than alternate day
doses of prednisolone up to 60 mg
on alternate days.
Reviewers' conclusions:A daily
dose of prednisolone l0 mg/day
a p p e a r s  t o  b e  e q u i v a l e n t  t o
m o d e r a t e - h i g h  d o s e  i n h a l e d
cor t i cos tero ids .  A l te rna te-day
doses of oral steroids and doses
< 5 mg/day appear to be less
effective than low-moderate dose
inhaled steroids.
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Background
Asthma is one of the commonest
chronic diseases inboth developed and
developing countries. Guidelines for the
management of chronic asthma have
been published in several countries and
all emphasise inhaled corticosteroids in
the control  of  symptoms and the
underlying inflammation of airways | 2.
In developing countries however the
use of inhaled steroids is often limited
by cost constraints. In South Africa the
Essential Drug List for Primary Care
limits the dose of inhaled steroids to a
maximum of 400mcg a day and in the
Western Cape doses of 800mcg a day
are limited at the primary care level to
asthma clinics upported by specialists3.
Although specialists are allowed to
prescribe higher doses, access to this
for a large number of patients with
asthma is not possible.The implication
of this is that patients with chronic
asthma remain poorly controlled on
low doses of inhaled steroids or they
must be controlled by the addition of
oral steroidsa.
The Health Department advocates the
use of oral steroids in preference to
inhaled for mild to moderate asthma 3:
"Many adults patients needing more
therapy for their asthma than only
bronchod i la to r  therapy ,  may be
m a i n t a i n e d  o n  a  l o w  d o s e  o r a l
prednisone (5 to 7.5mg per day or l0
to l5mg alternative days) without any
systemic side effects, even if used for
years  ( inc lud ing  bone dens i ty
de ter io ra t ion) .  Because o f  the
considerably higher costs of inhaled
corticosteroids, low dose prednisone
s h o u l d  b e  c o n s i d e r e d  i n  m i l d  t o
moderately severe asthma in adults."
This systematic review aims to assess
the evidence for this position, which is
c lear ly  in  cont rad ic t ion  to  most
published guidelines. lf low dose oral
s te ro ids  can be  jus t i f ied  then
developing countries may be able to
make considerable financial savings and
if this is not the case then it provides a
basis from which to motivate for the
availability of inhaled steroids without
restrictions. In order to answer this
question the review will first determine
the dosage of oral steroids required
to give a therapeutically equivalent
effect to inhaled steroids. Further
reviews wi l l  be necessary to ful ly
answer the question regarding the
relat ive safety of therapeut ical ly
equivalent dosages of inhaled and oral
steroids.
This systematic review was prepared
with the support of the Cochrane
Collaboration and is published as part
of The Cochrone Librory . lt will be
updated as more trials are either
published or identified s.
Types of interventions
RCTs,which compared inhaled steroids and
oral prednisolone or prcdnisone for the
treatment of chronic asthma, were
reviewed. The maximum dai ly dose
considercd for inhaled steroids was 2000
mqgand for oral steroids was 60 mg. Only
studies with adequately control led
prospective comparisons of the two
regimens in the same subjects were
chosen.Therefore those studies which
evaluated the steroid sparing effect of
adding inhaled to oral were not included.
Types of outcome mearunes
Measures of nocturnal and dayt ime
s y m p t o m  f r e q u e n c y ,  p e a k
e x p i r a t o r y  f l o w  ( P E F )  ( l l m i n ) ,
forced expiratory volume at one
second (FEV l)  ( l ) ,  v i tal  capacity
(VC) ( l ) ,  s low vi tal  capacity (SVC)
( l ) ,  n u m b e r  o f  a c u t e  a t t a c k s
requ i r ing  med ica l  a t ten t ion  and
qual i ty of l i fe assessments were
used to compare therapeut ical ly
equ iva len t  doses  o f  inha led  and
oral  steroids.
0bjectives
To determine the therapeutically equivalent doses of inhaled versus
oral steroids in the treatment of adults with chronic asthma.
Griteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of
at least 4 weeks duration.
Types of participants
Only RCTs with participants over the age
of l5 years and with chronic asthma were
included. Chronic asthma was defined as
fryper-responsiveness of the airways, which
nanoweasilyto awide range of stjmuli.This
may result in coughing, wheezing, chest-
tightness and shortness of breath.
- search strategy for identif ication of studies -
The Cochrane Collaboration Airways
Group conducted a search using the
terms: (drug del ivery systems OR
[(nebul i*  OR inhal* OR MDI) AND
oralx)] AND (steroidx OR corticos-
te ro id *  OR g lucoco r t i co id *  OR
beclomethasone OR betamethasone OR
fluticasone OR cortisone OR dexa-
methasone OR hydrocortisone OR
prednisolone OR prednisone OR
tr iamcinolone).  This search was
conducted in MEDLINE (1966-1999),
EMBASE (1980-1999) and CINAHL
( |  982- |  999).  The search included
CENTRAL a database containing
potent ial  RCTs obtained by hand
iearch ing  o f  journa ls  w i th in  the
Two independent reviewers (BM,AB)
screened the titles and abstracts of the
electronic search. From the results of
the  screened e lec t ron ic  search ,
b ib l iography  searches  and o ther
contacts, the reviewers independently
selected trials, which met previously
d  e f in  ed  inc lu  s  ion  c  r i te r ia ,  an  d
abstracted study characteristics and
outcome measures.
The fo l low ing  parameters  o f
methodological quality were assessed:
Cochrane Collaboration. All articles
were considered regardless of language.
Appropriate references from the
art ic les obtained, using the above
Methods of the review
Studies were assessed as having a low
risk of bias (A), a moderate risk of
bias (B) or high risk of bias (C) using
ttre following criteria as shovwr inTable l:
l. Were all patients who entered trial
accounted for and attributed at
conclusion?
2. Were pat ients analysed in the
groups  to  wh ich  they  were
randomised (intention to treat)?
3.Was the assessment of outcomes
blinded to type of treatment?
s e a r c h ,  w e r e  r e v i e w e d  a n d  t h e
a u t h o r s  o f  p u b l i s h e d  a s t h m a
management guidel ines as wel l  as
recognised experts approached for
additional studies.
4. Were the groups similar at the
start of the triall
5. Aside from the intervention were
the groups treated equallyl
Sub-groupAnalyses:
Study setting, study duration, disease
severity, type and doses of inhaled
and oral steroids, delivery system of
inhaled steroid, frequency of drug
del ivery, pr ior and concomitant
treatment were all noted.
Description of studies
The search strategy ielded 1285 trials I
from which l5 studies were requested I
and of these 5 were discarded leaving a
total of l0 studies in the review. The
included studies are summarised in
Table I and the excluded inTable ll.
Table I: Characteri*ics of included studies
Study Methods Participants Interventions Outcomes Notes
Bosman
et al. l3
Eriksson
et al.r5
Jenkins
et al.r*
Double blind
cross over.
Risk of bias:A,
Superiority
trial.
Double blind
cross over.
Risk of bias:A.
Superiority
trial.
Single blind
cross over.
Risk of bias:B.
Superiority
trial.
r7  (  r2M, sF) .
Mild to moderate
asthmatics. Prior
treatment
800mcg of
inhaled steroids.
22 (4M, r8F).
Moderate-severe
asthmatics. Prior
treatmene oral
steroids.
r8 (eM, eF)
Moderate to
severe asthmatics.
Prior treatment:
Beclomethasone
400mcg,
Prednisone up to
Smg/day in 4
Patients.
Beclomethasone 2000mcg vs.
Prednisone | Omg.Washout period
between treatments. Delivered by
aerosof x2lday.Treatment period 4
weeks. Concomitant treatment:
Bronchodilators.
Beclomethasone 300mcg vs.
Prednisolone 5mg. No washout
period between treatments. Delivered
by aerosol x3/day.Treatment period 3
weeks. Concom itant treatment:
Bronchodilators.
Beclomethasone | 200mcg vs.
Prednisone | 2.5mg.Washout period
given between treatments. Delivered
by aerosol 6 puffs x4 a day.Treatment
oeriod 3 weeks. Concomitant
treatmenc lntervention added to
prior treatment.
Diary Card: PEF
am & pm;
symPtom score.
Clinic visit:
FEV I, SVC.
Diary Card:
PEF am & pm,
symPtoms.
Clinic visit:
FEV IA/C/PEF
Diary Card:
Airflometer am
& pm, diurnal
variabiliry.
Clinic visit:
FEV I
3 patients
excluded from
analysis.Data
reported using
SEM and in
graphical form
Toble l: (continued)
Study Methods Participants lnterventions Outcomes Notes
Lahdensuo
et al.  '6
Lal et al.r7
BTTA.Is
Namsirikul
et a l .  12
Rosenhall
et al. re
Double blind
cross over,
Risk of bias:A.
Superiority
trial.
Double blind
cross over.
Risk of bias: B.
Superiority
trial.
Double blind
non-cross
over,
Risk of bias:A.
Equivalence
trial.
Double blind
cross over.
Risk of bias:A.
Superiority
trial.
Randomised
Blinding
unclear. Non-
cross over.
Risk of bias:C.
Superiority
trial.
r8  ( r3M,  sF )
Moderate - severe
asthmatics.
Prior treatment:
Prednisolone 5mg
(7 patients),
disodium
chromoclycate (2
patients).
40 (eM, 3 rF)
Severe asthmatics.
Prior treatment:
Prednisolone
7.5mg; disodium
chromoclycate
(3 | patients).
7s (37M, 38F)
Mild to moderate
asthmatics.
Prior treatment:
sodium
chromoclycate
(28 patients).
28 ( r2M, r6F)
Moderate
asthmatics.
Prior treatment:
No oral steroids.
r 7 ( r3M,4F )
Severe asthma.
Prior treatment:
oral steroids,
mean 5mg/day.
Beclomethasone 800mcg vs.
Prednisolone lOmg. No washout
period given between treatments.
Delivered by aerosol 4 puffs x4 a day.
Treatment period 2 weeks.
Concomitant herapy: Intervention
added to prior treatment.
Bronchodilators.
Beclomethasone 300mcg vs.
Prednisolone 7mg. No washout
period between treatments. Delivery
system aerosol (micronised powder)
x3 a day.Treatment period 4 weeks.
Concomitant therapy:
Bronchodilators. Use of
chromoclycate was unclear.
l) Placebo aerosol + Prednisone
5mg.
2) Beclomethasone l00mcg +
Placebo tablets.
3) Betamethasone valerate l00mcg +
Placebo tablets.
Patients were started on 4 double
puffs of aerosol + 4 tablets per day
and then reduced by I double puff +
I tablet weekly until not adequately
controlled when the dosage was
increased by I double puff + | tablet
to give the maintenance dose.This
dose was then evaluated for 24
weeks. Concomitant reatment:
Sodium chromoclycate and
bronchodilators.
l) Budesonide 400mcg vs.
Prednisolone 5mg.
2) Budesonide 800mcg vs.
Prednisolone l0mg.
Washout period given between
treatments. Delivery system tube
spacer x2 a day.Treatment period 3
weeks. Concomitant reatment:
Bronchodilators.
Budesonide 400mcg or 800mcg or
Prednisolone lOmg or 20m9.
No washout period recorded
between treatments. Delivery system
not stated.Treatment period 2
weeks. Concomitant reatment:
Bronchodilators.
I Diary Card -
I PEF am & em;
I symProm
I score,
| :::"'n'0""'"'
Diary Card -
PEF am & pm;
bronchodilator
usage. Clinic
visit FEVI and
vc.
Number of
"failure days";
% patients
given
prednisone
short course; %
patients whose
maintenance
dose was
increased.
Mean monthly
PEE
Diary Card -
PEF am & pm;
symPtom
score,
bronchodilator
usage. Clinic
visic PEF, FEV I
and FVC.
Diary Card -
PEF am & pm;
symPtom
scores,
bronchodilator
use. Clinic visit:
FEVI andVC.
Data was
reported with
SEM not SD.
Data reported
with range not
SD.
Data reported
without SD.
Data
presented
graphically.
Table l: (continued)
Study Methods Participants lnterventions Outcomes Notes
Toogood
( l) et al.2o
Toogood
(2)."
Double blind
cross over.
Risk of bias:A.
Equivalence
trial.
Double blind
cross over.
Risk of bias:C.
Equivalence
trial.
17 non oral
steroid
dependent (NON
DEP) and l7 oral
steroid
dependent (DEP).
(20M, r4F)
Moderate and
severe asthmatics
Prior treatment:
Beclomethasone.
Number of
participants and
disease severity
unclear. Prior
treatmenc l5mg
alternate day
Prednisone and
800mcg
Beclomethasone.
In DEP group:
Budesonide 800mcg vs Prednisone
l0mg; Budesonide l600mcg vs
Prednisone 20mg; Budesonide
3200mcg vs Prednisone 40m9.
Washout period given between
treatments.
In NON DEP group:
Budesonide 400mcg vs Prednisone
7.5mg; Budesonide 800mcg vs
Prednisone | 5mg; Budesonide
l600mcg vs Prednisone 30mg.
Defivered by nebuhaler x4lday.
Treatment period: 2 weeks.
Concomitant treatment:
Bronchodilators.
Prednisone given on alternate days.
Budesonide 800mcg vs Prednisone
l5mg; Budesonide l600mcg vs
Prednisone 30mg; Budesonide
3200mcg vs Prednisone 60mg.
No washout period recorded
between treatments.
Delivered by cone spacer x4lday.
Treatment period: 2 weeks.
Concomitant reatmenc unclear,
Diary Card:
lower am and
pm PEFR;
symPtom
frequency; mean
severity of
asthma using
visual analog
scale; during
week 2 of each
treatment
period. Clinic
visic FEVI.
DiaryC-ard:
Asthma frequency
(attack per
week) Mean
ssrerity of asthma
(average score
per week using
visual analog
scale).
ClinicVisit FEVI.
Data
presented
graphically.
Data
presented
graphically.
Table ll: Charcaeristics of excluded studies.
Study Reason for exclusion
Cooper et al.6
Prakash et al.7
Takashashi et al.8
Wempe et al.e
Wilmsmeyer et al.ro
Not a RCT and does not test therapeutic equivalence.
Outcome measures inadequately reported.
Not a RCT
Comparison of steroids not primary purpose of study.
Main focus on effectiveness of bronchodilators.
Does not test therapeutic equivalence.
Six of the studies were rated as having a
low risk of bias (A), two of the studies
as a moderate risk (B) and two of the
studies as a high risk of bias (C). ln the 2
studies rated as "B" one was only single
blind and the other had 2 patients
ethodological  qual i ty of included studies
unaccounted for at the end of the trial.
In the two studies rated as"C",Toogood
(2) did not c lar i fy the number of
pafticipants or the severity of asthma nd
Rosenhall did not clarify the process of
blinding. Both studies did not present
their basic dataAlthough the Lahdensuo
study was rated an "A" according to our
criteria, his study design failed to prevent
considerable carry-over effects between
the two treatments and this limia the
usefulness of his conclusions.
Results
Six of the l0 studies compared aily oral
steroids with inhaled beclomethasone
and three with budesonide. ln the
Toogood (2) study alternate day
prednisone was compared with inhaled
budeson ider r .  On ly  the  s tud ies  by
Namsi r i ku l ,  Bosman and Jenk ins
presented ata that could be entered into
a metaview and the data from these
studies is summarised in Table l l l .
Namsirikul's study concluded that inhaled
budenoside 400mcg was more potent
than prednisolone 5mg, but that
budenoside 800mcg was therapeutically
equivalent to prednisolone l0rng' t .
Bosman's tudy concluded that 2000mcg
of  inha led  bec lomethasone was
therapeutically equivalent to | Omg of oral
prednisone, apart from superiority of
beclomethasone for the morning PEF|3.
Jenkin's study concluded that inhaled
beclomethasone l200mcg was
therapeutically equivalent to l2.5mg of
oral prednisonera.
Data from Eriksson, Lahdensuo, Lal,
Namsi r i ku l ,  Bosman and Jenk ins  is
presented in Table lY (overleof). ln
Eriksson's study rs it was concluded that
300mcg of inhaled beclomethasone gives
a better therapeutic effect than 5mg of
oral prednisolone. Lahdensuo's study
reported his data according to two
groupsr5. Group A had beclomethasone
800mcg and then prednisolone | Omg and
group B received the same drugs in
reverse order.The effect on the morning
PEF values was not significantly different
between the drugs, but the effect on the
evening PEF values was significantly better
with prednisolone.The study concluded
that 800mcg of inhaled beclomethasone
was therapeutically equivalent to lOmg
of oral  prednisolone. Lal 's study
compared beclomethasone 300mcg and
prednisolone Tmgr Tlhis study concluded
that 300mcg of inhaled beclomethasone
is therapeutically equivalent o 7mg of
oral prednisone.
In the BTTA Study data for 67 patients
were analysed;the r maining 8 patients
were withdrawn because of side effects
and poor control of asthmar8. In the
BTTA study, data from diary cards
(frequency of use of inhaled and oral
steroids, asthma severity and additlonal
use of cofticosteroids) and clinic visits
(monthly PEF) were analysed. Failure day
was defined as days on which > 4 puffs
of bronchodilator were used;or days on
which oral and inhaled steroid therapies
were increased to obtain a new stable
dose. On average there was less than I
'failure day' per month per patient in
each ofthe three test groupsJhere was
no signi f icant di f ference between
treatment groups whose maintenance
dose was increased (between 14% and
26% of pat ients) and for those
prescribed short course prednisone
(between 4% and l0% of patiena).The
mean monthly PEF was much the same
in each troup: 302 for patients who
received prednisone,300 for those who
used beclomethasone dipropionate and
270 who were treated with
betamethasone valerate. On average,
400mcg of inhaled cort icosteroid
provided control of asthma similar to
that provided by 7.5mg of prednisone.
The different study design precluded
presenration of the data inTable lll.
In Rosenhall's study data for l6 patients
were analysedre. Basic data on his results
were not provided.When compared to
base l ine ,  the  morn ing  PEF had
significantly improved with the two high
dose treatments (budenoside 800mcg
and prednisolone 20mg) but not with
the low dose (budenoside 400mcg and
prednisolone | 0mg) treatments. Overall
budenoside 400mg was found to be
equipotent o prednisolone lOmg (as
wellas baseline) and budenoside 800mg
gave the same additional effect as
prednisolone 20mg.
In theToogood(l) study data from two
groups of 17 patients were analysed2o.
The DEP group was defined as the
patients previously dependent on regular
Toble lll: Metaview of Seleced Studies
Review: lnhabd vs orel steroida fol adults with chronic
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dose of prednisone and the NON DEP
group as pat ients not previously
dependent on prednisone. Both DEP and
NON DEP groups demonstrated ose-
dependent improvement in the mean
frequency and severi ty of asthma
symptoms, FEV I and lower morning and
evening PEFs. Basic data was not
provided and results were given in
graphical form. The study conclusions
were based on the potency ratio of the
number of milligrams of prednisone that
were equivalentto budenoside 1000 mcg
per day.In the DEP group the following
potency ratios for different outcomes
were given: Lower PEF am and pm
I 36mg, FEV I S5mg,symptom freguency
35mg, mean severity of asthma symptoms
27mg. For the NON DEP: Lower PEF
am and pm 53mg, FEVI 9lmg, s),mptom
frequency 58mg,mean severity of asthma
symptoms 42mg.When combining both
DEP and NON DEP for all outcome
measure an equivalent potency of 57.5mg
of prednisone was obtained for l000mcg
of budesonide.
In the'l'icogood(2) study data from 14
patients were analysedrr. Basic data was
not provided and results were given in
graphicalform. From baseline the inhaled
budenos ide  800mcg produced a
significant and sustained increase in FEV | ,
but there was no accompanying
reduct ion in asthma frequency or
severity.When patients were prescribed
alternate day prednisone, FEVI, asthma
frequency and severity deteriorated
despite increasing doses.The differences
between the budenoside and prednisone
were statistically significant at most of the
individual dose levels (p<0.05). Patients
on inha led  budenos ide  showed
statistically less asthmatic disability than
with oral alternate-day prednisone
(p=0.05) .  Budenos ide  800mcg or
l600mcg/day proved more effective than
any ofthe three doses used in terms of
the effects on FEVI (p=0.06),frequency
of asthma attacks (p=0.02) and mean
severity of asthma (p=0.008).
Tshle l'& , Datq from lncluded etudiel (not prorented,in metaview)"
Study Intervention Diary-am PEF Diary-am PEF Clinic-FEVI Clinic-VC Clinic-PEF
Eriksson
Lahdensuo:
GroupA
Lahdensuo:
Group B
Lal
Namsirikul
Namsirikul
Bosman
Jenkins
BDP
300mcg vs
Pred 5mg
BDP
800mcg vs
Pred l0mg
BDP
800mcg vs
Pred l0mg
BDP
300mcg vs
Pred 7mg
BUD
400mcg vs
Pred 5mg
BUD 800mcg vs
Pred lOmg
Pred lOmg BDP
2000mcg vs
Pred l0mg
BDP
2000mcg vs
Pred l2.5mg
BDP 266
Pred 243#
Base 220 se 30.9
BDP 272 se 22. I
Pred315se26, l
Base
BDP
Pred
BDP
Pred
250 se 19
353 se 28.2
302 se 24.4
288 (r2s-s32)
28r (r24-s0e)
375 sd 75
361 sd 82
397 sd 82
399 sd 7l
BUD
Pred
BUD
Pred
BeEDPSl sd 18
BefPred 82 sd 15
AftBDP 92 sd 15
AftPred 86 sd I lx
PreBase 44.3 sd 40.8
PreBDP60.l sd46.9
PrePred 60.9 sd 48
PostBase 67.2sd53.2
PostBDP 77.2 sd 52.1
PostPrcd 78.6 sd 54.3@
BDP 326
Pred 306#
Base 336 se 44.8
BDP 373 se 30.3
Pred 421 se 25.3
Base 362 se 26.7
BDP 440 se 30.9
Pred 395 se 37.6
BDP3r0(rs0-s38)
Pred 293 (139-501)
BUD 388 sd 72
Pred 390 sd 74
BUD 408 sd 79
Pred 417 sd 68
PreBase 63.2 sd 52.5
PTeBDP 69.6 sd 54.4
PrePred 7 | .5 sd 44.3
PTeBDP 1.97 se 0. l8
PrePred 1.79 se 0.18
PostBDP 2.30 se 0.22
PostPred 2.07 se 0.27
BDP 2.38 (r .0-4.8)
Pred 2,34 (0.9-4.7)
BUD 73 sd 14
Pred 73 sd 14
BUD 75 sd 15
Pred 74 sd 14
BefBDP 85 sd 18
BefPred 86 sd 16
AftBDP 93 sd 18
AftPred 9l sd l5x
Base 1.9 sd 0.7
BDP 2.2 sd 0.8
Pred 2.0 sd 0.8
PTeBDP 2.73 se 0.22
PrePred 2.52 se 0.21#
PostBDP 3.| 5 se 0. | 8
PostPred 2,95 se 0. | 9
BDP 3.s4 (2.0.s.7) |Pred 3.48 (l.s-s.e) |
I
I
I
BUD 88 sd 13 |
Pred 89 sd 12 |
I
I
I
BUD 89 sd 12 |
Pred 90 sd 13$ |
I
I
BefBDP 4.74 sd 1.29 |
BefPred4.67sd l.4l I
AttBDP 4.77 sd 1.36 |
AftPred 4.77 sd 1.37 |
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Discussion
T h e  d e s i g n  o f  t r i a l s  t o  a s s e s s
equ i va lence  o f  t r ea tmen ts  has  a
number of important methodological
i s s u e s .  O n e  r e q u i r e m e n t  o f
equivalence studies is  the need for
l imi ts  of  equivalence to be set ,  a
pr ior i .Absolute equivalence,  i .e .  zero
difference between treatments wil l
not occur, so it is necessary to set
l i m i t s  a b o v e  a n d  b e l o w  z e r o
di f ference wi th in which equivalence
can  be  assumed .  These  l im i t s  a re
u s u a l l y  s e t  a t  +  5 0 %  o f  t h e
therapeutic effect of the treatment.
S u c h  l i m i t s  h a v e  n o t  y e t  b e e n
established for steroid therapy for
asthma. In the absence of  empir ica l ly
der ived l imi ts .  va lues of  + 0. l5  l i t res
for FEV I or + l5 l/min for PEFR might
b e  r e a s o n a b l e  c o n s e r v a t i v e
estimates2r. A further consideration
i s  t he  e f f ec t  o f  f l oo r  and  ce i l i ng
ef fects.  In  the former,  inadequate
doses of drug may be given, leading
to a fa lse assumpt ion of  equivalence,
neither dose being effective. Ceil ing
effects occur when a drug is close to
the top of its dose response curve.
Ve ry  l a rge  i nc reases  i n  dose  w i l l
produce small increases in effect that
w i l l  be  i nsu f f i c i en t  t o  move  the
difference between the efficacy of the
two treatments outside the l imits of
e q u i v a l e n c e .  F a l s e  e q u i v a l e n c e  i s
s  h  own  by  e  q  u  a  l l y  i n  e f f e  c t i ve
treatment as demonstrated by the
lower dosage schedule in  Rosenhal l 's
study,  which a lso scored a h igh r isk
of bias.A ceiling effect may be relevant
in Bosman's study where a dose of
2000mcg is used in a study population
who were a l ready wel l  contro l led.
Unfortunately,very little is known about
dose-response effects for steroids in
chronic asthmalhus 800mcg/day inhaled
steroid may lie towards the top of a dose
response curve for inhaled steroid and
produce an effect indistinguishable from
that produced by prednisolone in a dose
of 40 mglday.
This l imi tat ion is  compounded by the
need for  larger  sample s izes in  t r ia ls
t h a t  a s s e s s  e q u i v a l e n c e  a n d  n o t
d i f f e r e n c e 2 2 .  l n  a d d i t i o n  t o  t h e
methodological quality a number of
other factors must be considered in
t ry ing to expla in the d ivers i ty  of
f ind ings.The inc luded studies a l l  had
smal l  sample s izes and were unable
to be combined in a meta-analysis due
to s igni f icant  heterogenei ty  wi th
d i f f e r e n c e s  i n  p h a r m a c o k i n e t i c
properties of drugs, dosages, delivery
systems and outcome measurements.
In addition the review was limited by
the poor repor t ing of  basic  data,
f a i l u r e  t o  a d e q u a t e l y  r e p o r t  o n
al locat ion concealment  and inabi l i ty
to access the basic  data f rom the
o r i g i n a l  a u t h o r s 2 3 .  T h e  p a t i e n t
populat ions inc luded in the studies
are descr ibed as mi ld.  moderate or
severe asthmatics, but the basis of this
c lass i f icat ion is  unclear  and open to
interpretation.The dosing schedule of
4 times a day has been shown to be
up to 8 times as potent as the same
dose given twice a day and the studies
varied considerably in this respect24.
The  de l i ve ry  sys tem a l so  va r i ed
between studies, with Toogood( 1,2)
a n d  N a m s i r i k u l  b e i n g  t h e  o n l y
researchers to use a spacer device.
Spacer devices have been shown to
double the anti-asthmatic potency of
budesonide 2s however the use of a
spacer is  not  able to fu l ly  expla in the
re lat ive ly  h igh potency of  inhaled
budesonide in the Toogood( | ) study.
The interpretation of Toogood( l) 's
study is  l imi ted by the method of
reporting the results - as the dose of
prednisone equivalent  to  1000 mcg
budesonide.A number of factors may
have  i n f l uenced  these  resu l t s .  As
pointed out already, the assumption
of perfect equivalence is not correct.
There are measurement and sampling
errors in  a l l  t r ia ls .  In  the presence of
very smal l  pat ient  numbers,  as in  th is
study, the confidence intervals around
the difference between the two drugs
w i l l  be  w ide .  Thus  the re  i s  a  h igh
p robab i l i t y  o f  one  d rug  appea r i ng
more effective than another. Dose-
response  e f f ec t s  may  a l so  have
played a role.The prednisone doses
in this study ranged l0-40 mg/day.lt
i s  qu i t e  poss ib le  t ha t  t he  dose -
response curve for  prednisone is
rather  f la t  above 20 mg/day,  so
budeson ide  1000  mcg /day  cou ld
appear equivalent to prednisone in
doses of 20 mglday and 40 mglday.
Thirdly, the results were expressed
as a ratio.This permits an apparent
inflation of effects if the denominator
is  smal l .  As can be seen f rom the
resul ts  f rom other  s tudies in  th is
review, the degree of scatter around
the response to s tero ids may be
large.Thus a chance'under-estimate'
of  the numerator  coupled wi th a
c h a n c e ' o v e r - e s t i m a t e '  o f  t h e
denominator wil l give an apparently
large ratio of effect in favour of the
numerator .  These factors and the
absence  o f  bas i c  measu red  da ta
mean the resul ts  of  th is  t r ia l  are
effectively u ni nterpretable.
Studies also differed in their use of
concomitant  therapy;  in  par t icu lar
the Jenkins and Lahdensuo studies
added  the  i n te rven t i on  t o  p r i o r
t h e r a p y  w i t h  i n h a l e d  a n d  o r a l
s t e r o i d s .  V a r i a t i o n  i n  t h e
determinat ion of  equivalence may
also depend on the inc lus ion of  a
washout period in the study design
a n d  t y p e  o f  o u t c o m e  m e a s u r e
chosen. When designing the study,
absence ofa proper washout  per iod
minimises treatment effects because
of carryover effect or slow response,
which would favour equivalence.The
evaluat ion of  equivalence wi l l  a lso
va ry  depend ing  on  the  ou tcome
measu re  used .  I n  t he  Toogood ( l )
study this was well demonstrated
with a five-fold difference between
equivalence in d i f ferent  outcome
measures.  ln  a l l  these studies which
compare inhaled with oral therapy
in the same subjects there may be
wide var iat ion in  the actual  inhaled
drug delivered relative to the stated
dose given.The actual deposition may
vary with the type of delivery device
and particle characteristics, its use
by the patient as well as the physical
characteristics of the patient26. lt is
difficult therefore to define the actual
inhaled dose being compared to the
oral regime.
Alternate day treatment due to its
short duration of action is unable to
induce remission in a person with
active and uncontrolled inflammation
and is best sui ted to maintaining
remiss ion  once ach ieved by  da i l y
therapy2T. lt cannot therefore be seen
as an alternative to daily therapy but
r a t h e r  a  d e s i r e d  e n d p o i n t  o n c e
r e m i s s i o n  i s  o b t a i n e d .  T h e
T o o g o o d ( 2 )  s t u d y  s h o w e d  a
consistent advantage to daily inhaled
b u d e s o n i d e  o v e r  a l t e r n a t e  d a y
predn isone even up  to  60mg on
alternate days.
ls it possible to draw any conclusions
from these trialsl A firm conclusion
cannot be drawn, but a pattern emerges
from these data. Three studies with a
washout phase (Namsirikul, Bosman,
Jenkins) suggest that prednisolone l0-
12.5 mg/day is equivalent to
beclomethasone 800-2000 mcg/day. In
the studies without a washout (Lal and
BTTA), prednisolone 7- l0mg/day
was equivalent o 300-400 mcglday
of  bec lomethasone or budeson ide .
In the f i rst  part  of  the Group A of
the Lahdensuo study, the change in
P E F  f r o m  b a s e l i n e  t o
beclomethasone 800 mcg/day was
52 l /m in .  In  the  f i rs t  par t  o f  the
Group B of the Lahdensuo study,
the change in PEF from basel ine to
prednisolone l0 mg/day was 48 l /
m i n .  T h u s  s i m i l a r  e f f i c a c y  w a s
obtained in this tr ia l .  Overal l ,  there
appears to be equivalence between
7.5-12.5 mglday prednisolone and
300-2000 mcg/day inhaled steroid.
T h i s  c o n c l u s i o n  s h o u l d  b e  s e t
against he results from two studies
(one w i th  a  washout  (Namsi r i ku l )
a n d  o n e  w i t h o u t  ( E r i k s s o n ) )  i n
wh ich  doses  o f  inha led  s te ro id  in
the range 300-400 mcg/day were
more effective that prednisolone 5mg/
day. Finally, it should be noted that
inhaled therapy appeared to be more
effective than oral prednisone in doses
up to 60mg on alternate days.
The s t ronges t  conc lus ions  to  be
drawn f rom the  s tudy  are  tha t
p r e d n i s o l o n e  i n  a  d o s e  o f
approximately l0 mg day is equivalent
to moderate-high doses of inhaled
s t e r o i d s .  L o w e r  d o s e s  o f
prednisolone and any alternate day
dose appear to be less effective than
even moderate doses of inhaled steroids.
lf this review is correct in concludingthat
prednisolone l0 mg/day has equivalent
efficacy to that from moderate dose
inhaled steroids, the next question
concerns side effects. Unfortunately the
data from the trials reviewed here give
no in depth information concerning this
important issue. Few side effects would
be expected at the doses used in most
of these studies over the short time
period studied, so even if these were
repor ted ,  they  wou ld  g ive  l i t t le
indication of the longterm probability
of side effects. To complement the
efficacy data reviewed here,side effects
of long term oral steroids in the doses
used here can only be obtained from
other studies,most probably in diseases
other than asthma.There will, however,
be problems when extrapolating from
other diseases in which there may be
a n  i n t e r a c t i o n  b e t w e e n  d i s e a s e
effects and side effects, for example
in rheumatoid arthritis2e.Age will also
be impor tan t  s ince  s te ro id  s ide
effects such as cataracts.diabetes and
osteoporosis may be age dependent.
In this context, it should be noted
that inhaled steroids do have side
e f f e c t s  t h e m s e l v e s .  A  r e c e n t
Cochrane review has shown that
l inear growth is reduced in chi ldren
with asthma given beclomethasone
400 mcg/day28.
lmplications for practice
What practical advice can be giren to tlre
doctor praaising in a developing country
scenario?A daily dose of prednisolone l0
mglday appears to be equivalent o
moderate-high dose inhaled cortico-
steroids. Alternate-day doses of oral
steroids and doses < 5 mg/day appear to
be less effective than low-moderate dose
inhaled steroids. At present herc is no
er/denceaboutdre long-term effecs of oral
steroids in aduhswith asthma.ffthere is no
alternative to oral steroids. the lowest
effeaive dose (which appears to be 7.5 mg/
dry) should be prescribed.
Reviewer's Conclusions
lmplications for research
T h i s  r e v i e w  d e m o n s t r a t e s  t h a t
t h e r e  i s  l i t t l e  e v i d e n c e  t o
a c c u r a t e l y  d e t e r m i n e  t h e
the rapeu t i ca l l y  equ i va len t  dosage
o f  i nha led  and  o ra l  s te ro ids .Wou ld
i t  however be eth ica l ly  just i f ied in
the year  2000 to recommend that
f u r t h e r  r e s e a r c h  b e  d o n e  t o
d e t e r m i n e  t h i s  e q u i v a l e n c e l  A
s y s t e m a t i c  r e v i e w  o f  t h e  s i d e
effects of inhaled and low dose oral
s te ro ids  wou ld  he lp  phys i c i ans  to
we igh  the  po ten t i a l  bene f i t  and
harm to thei r  pat ient .
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